Trends in catheter ablation for atrial fibrillation in the United States.

BACKGROUND There are few data on the use of catheter ablation for atrial fibrillation (AF) in the United States. We analyzed data from the National Hospital Discharge Survey (NHDS) to examine trends in the rate of catheter ablation for hospitalized patients with AF over a 15-year period. OBJECTIVE To examine rates of catheter ablation in patients with AF over time. DESIGN All adult patients in the NHDS with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for AF from the years 1990 to 2005 were identified and assessed for the presence of a cardiac catheter ablation procedure code. Clinical characteristics associated with ablation were identified and multivariable logistic regression used to determine trends in the rate of ablation therapy over time. RESULTS We identified 269,471 adults with AF. The rate of catheter ablation in AF patients increased from 0.06% in 1990 to 0.79% in 2005 (P < 0.001 for trend). Compared to those not undergoing ablation, ablated patients were younger (mean age 66 versus 76 years; P < 0.001), more likely to be male (57% versus 43%; P < 0.001), have private insurance (22% versus 11%; P < 0.001), and have a none of the following stroke risk factors: congestive heart failure, hypertension, age >75 years, diabetes mellitus, or stroke/transient ischemic attack (37% versus 16%; P < 0.001). Catheter ablation in AF patients increased by 15% per year over the time period (95% confidence interval [CI], 13%-16%) and across all age groups, including in patients age > or =80 years (0.0% in 1990 and 0.26% in 2005; P < 0.001 for trend). CONCLUSIONS The rate of catheter ablation in patients with AF is increasing significantly over time, even in the oldest patients. Medicine.

[1]  I. V. Van Gelder,et al.  Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. , 1991, The American journal of cardiology.

[2]  H. Crijns,et al.  Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. , 1996, Archives of internal medicine.

[3]  Thomas Lavergne,et al.  Cost of care distribution in atrial fibrillation patients: the COCAF study , 2004 .

[4]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[5]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[6]  R B D'Agostino,et al.  Impact of atrial fibrillation on mortality, stroke, and medical costs. , 1998, Archives of internal medicine.

[7]  A. Russo,et al.  Characteristics of Patients Undergoing Atrial Fibrillation Ablation: Trends Over a Seven‐Year Period 1999–2005 , 2007, Journal of cardiovascular electrophysiology.

[8]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[9]  M. Chung,et al.  Safety and efficacy of radiofrequency energy catheter ablation of atrial fibrillation in patients with pacemakers and implantable cardiac defibrillators. , 2005, Heart rhythm.

[10]  F. Morady,et al.  Atrial fibrillation: Catheter ablation , 2006, Journal of Interventional Cardiac Electrophysiology.

[11]  Prashanthan Sanders,et al.  Catheter ablation for atrial fibrillation in congestive heart failure. , 2004, The New England journal of medicine.

[12]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[13]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[14]  Gianni Tognoni,et al.  Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2005 .

[15]  Douglas Packer,et al.  Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation.

[16]  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.

[17]  J. Gardin,et al.  Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). , 1994, The American journal of cardiology.

[18]  Frank Bogun,et al.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation. , 2006, The New England journal of medicine.

[19]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomized controlled trial☆ , 2003 .

[20]  F. Sacher,et al.  Catheter ablation for atrial fibrillation. , 2007, Circulation.

[21]  Douglas L Packer,et al.  Progress in Nonpharmacologic Therapy of Atrial Fibrillation , 2003, Journal of cardiovascular electrophysiology.

[22]  J. Ruskin,et al.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.

[23]  C. Morillo,et al.  Cost Comparison of Catheter Ablation and Medical Therapy in Atrial Fibrillation , 2007, Journal of cardiovascular electrophysiology.

[24]  Colin Berry,et al.  Atrial fibrillation in the elderly , 2003 .

[25]  G. Kay,et al.  Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis. , 2000, Circulation.

[26]  S Nattel,et al.  Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. , 2000, The New England journal of medicine.

[27]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .

[28]  Elia Biganzoli,et al.  Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.

[29]  V. Santinelli,et al.  A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. , 2006, Journal of the American College of Cardiology.

[30]  C. Good,et al.  Amiodarone to prevent recurrence of atrial fibrillation. , 2000, The New England journal of medicine.

[31]  Simon Stewart,et al.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. , 2002, The American journal of medicine.

[32]  Fred Kusumoto,et al.  Survey of Physician Experience, Trends and Outcomes with Atrial Fibrillation Ablation , 2005, Journal of Interventional Cardiac Electrophysiology.